Dr. Duda to apply deep expertise in rare and immune-mediated diseasesNEWTON, Mass. and WÄDENSWIL, Switzerland , Jan. 08, 2026 (GLOBE NEWSWIRE) -- GlycoEra AG, a biotechnology company pioneering ...

Seven terminally ill people drank the potion that was supposed to end their lives and…woke up? How? Why? When?

Alzheimer’s disease biomarkers measured from finger-prick dried blood samples closely match standard plasma tests and predict ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

Blood biomarkers like p-tau217 are emerging as a way to detect Alzheimer's disease. The first FDA-approved blood-based ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

Eisai and Biogen (BIIB) recently reported that Chinese regulators accepted a Biologics License Application for a subcutaneous version of LEQEMBI, a development that brings attention to Biogen’s ...

Discover why Biogen Inc.'s stock surged 15% in 2025, driven by Skyclarys sales. Explore its strong growth potential and ...

Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

As they prepare for the J.P. Morgan Healthcare Conference next week, biotech leaders and analysts say companies are better ...